Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Cosentyx will soon see its U.S. patent expire, but Novartis does have newer medicines that should help drive top-line growth. These include Fabhalta, a treatment for paroxysmal nocturnal ...

An FDA advisory committee panel is scheduled to discuss the merits of Novartis’ oral factor B inhibitor Fabhalta in the rare kidney disease C3 glomerulopathy (C3G). The Cardiovascular and Renal ...